Our principal, Ms. Pauli Wong, was invited to speak at the Hong Kong Life Sciences Society (HKLSS) Summer Internship Program 2024 on “Unlocking Patent Law: Exploring IP Career Paths” in July. This program aims to cultivate young talents to drive life sciences innovation. In addition, she participated in the discussion session titled “Evolving Landscape – Investment Outlook for the Healthcare and Life Sciences Sectors” alongside Mr. Tian Tan, the Vice President of NF Trinity.

Pauli shared her career journey becoming a patent attorney at Eagle IP, from an HKU biotech graduate and a scientist with CK Life Sciences. She provided an introduction to intellectual property, particularly patents, and life sciences challenges we are facing, and how to pursue a career path in patent law. By sharing her own experiences, Pauli offered valuable insights and guidance to the aspiring interns to appreciate the importance of IP and consider a career path in patent law.

我们的过去活动

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

2025年11月26日

Jennifer Che has been Recognized as IAM Global Leaders 2026

2025年11月4日

Eagle IP is Coming to San Francisco and Washington DC!

2025年10月15日

Jennifer Che has been listed on the IAM Strategy 300

2025年8月15日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

2025年7月3日

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

2025年6月13日

Recommended Insights

Finally a unified “Court of Appeal” for technology IP in China

2019年1月22日
On October 26, 2018, China’s Supreme People’s Court (“SPC”) received approval to establish a specialized intellectual property court within the SPC to handle appeal cases involving technology-related IP for both civil (e.g., patent infringement) and administrative (e.g., patent invalidity) judgments. Technology-related IP includes invention patents, utility models, new plant species, IC design, trade secret, software, […]
阅读更多 >

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
阅读更多 >

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

2024年6月27日
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
阅读更多 >

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
阅读更多 >
Top crossarrow-right